Suppliers / Rampex Labs

Rampex Labs

India 144 employees Updated 9 July 2026

Rampex Labs is an API manufacturer based in India. It holds one active US drug master file and 2 valid CEPs across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 27 June 2024 as VAI.

1
active US DMFs
2
valid CEPs
4
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 27 June 2024 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Anakapalli, India Not on file
Parawada Village, India Not on file
Sangareddy, India 3008479404
Anakapalli, India 3010633689

What they file, and where

Molecule Regulators Docs
Olanzapine EDQM 2
Chlorzoxazone US FDA 1

Also appears on these molecule pages

Chlorzoxazone API Olanzapine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Rampex Labs comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 27 June 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates